Document is current
Any future updates will be listed below
-
Authors
Slon-Campos, Jose Luis
Dejnirattisai, Wanwisa
Jagger, Brett W.
López-Camacho, César https://orcid.org/0000-0001-7932-2341
Wongwiwat, Wiyada
Durnell, Lorellin A.
Winkler, Emma S.
Chen, Rita E.
Reyes-Sandoval, Arturo https://orcid.org/0000-0002-2648-1696
Rey, Felix A.
Diamond, Michael S. https://orcid.org/0000-0002-8791-3165
Mongkolsapaya, Juthathip https://orcid.org/0000-0003-3416-9480
Screaton, Gavin R. https://orcid.org/0000-0002-3549-4309
-
Funding
Funding for this research was provided by:
Wellcome Trust (203224/Z/16/Z)
Wellcome Trust (095541/A/11/Z)
Wellcome Trust (203224/Z/16/Z)
U.S. Department of Health & Human Services | National Institutes of Health (T32 AI007172)
U.S. Department of Health & Human Services | National Institutes of Health (R01 AI073755)
U.S. Department of Health & Human Services | National Institutes of Health (R01 AI127828)
U.S. Department of Health & Human Services | National Institutes of Health (R01 HD091218)
UK Department of Health and Social Care
French Government’s Investissement d’Avenir Programme (Labex Integrative Biology of Emerging Infectious Diseases, IBEID, grant ANR-10-LABX-62-IBEID 4E AAP
MRC-Newton fund
- License Information
-
More Information
Article History
Received: 6 June 2019
Accepted: 22 July 2019
First Online: 2 September 2019
Competing interests
: G.R.S., F.A.R. and J.M. are named inventors on a patent owned by Imperial College London and Institut Pasteur describing the EDE and its use as a potential immunogen (application number EP3172229A1). G.R.S. sits on the advisory board of GSK Vaccines. M.S.D. is a consultant for Inbios and Atreca, and sits on the Scientific Advisory Board at Moderna. The remaining authors declare no competing interests.
